Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price reductions under the Inflation Reduction Act, which would lead to a … ...
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...
The firm believes the “real culprit” for Merck shares remaining under pressure is Keytruda’s 2028 patent expiration. Despite the company building out its pipeline, past precedence shows the ...
The safety profile of the combination therapy remains consistent, with no new adverse effects observed. Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally ...
The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...
There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...
MSD’s Keytruda initially gained approval in Canada in 2015. Credit: JHVEPhoto/Shutterstock. Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating ...
NEW YORK – Bicara Therapeutics said Tuesday that it began treating patients in a Phase II/III trial testing the activity of its EGFR- and TGF-β-directed bifunctional antibody ficerafusp alfa with ...
Licensing deals happen all the time in the biotech industry, but few involve medicines that could challenge the world's best-selling medicine, Keytruda, in its most important market. That's what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback